The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
According to an Injury Surveillance Report by NCA last year, 14.75 % of players sustained shoulder injuries, 13.11% of players sustained knee injuries and almost 74 % players suffer from career-threatening Anterior Cruciate Ligament (ACL) injuries in the 1st two years of return to sport
Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
A total of 17 labs will be operational across the country by this month
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Subscribe To Our Newsletter & Stay Updated
